LOS Homepage

Advocacy

Move the Needle on Key Policy Priorities

Check Back for Updates!

LOS Statewide Case Presentation

FDA Approves pirtobrutinib for Chronic Lymphocytic Leukemia + Small Lymphocytic Lymphoma

FDA Approves Nirogacestat for Desmoid Tumors

FDA Approves Capivasertib + Fulvestrant for Breast Cancer

FDA Approves Pembrolizumab + Chemotherapy for HER2-negative GEJ Junction Adenocarcinoma

FDA Approves Repotrectinib for ROS1-positive NSCLC

Is It Time to Cancel the Term “A Cure for Cancer”